Quantum-Si to Participate in the Canaccord Genuity 45 th Annual Growth Conference
Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer will be taking one-on-one meetings throughout the day on Tuesday, August 12, 2025 and will participate in a fireside chat on the same day at 4:00 PM Eastern Time.
A live and archived webcast of the event will be available in the 'Investors' section of the Quantum-Si website under Events & Presentations.
About Quantum-Si Incorporated
Quantum-Si is transforming proteomics with a benchtop platform that brings single-molecule protein analysis to every lab, everywhere. The Company's platform enables real-time kinetic-based detection and allows researchers to move beyond traditional, multistep workflows and directly access dynamic, functional protein insights with unparalleled resolution. By making protein analysis simpler, faster, and more informative, Quantum-Si is accelerating proteomic discoveries to improve the way we live. Learn more at quantum-si.com or follow us on LinkedIn or X.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
22 minutes ago
- Business Wire
A.forall Announces the Direct Commercialization of Sodium Acetate Injection 2mEq/mL
WHITE BEAR LAKE, Minn.--(BUSINESS WIRE)--Through its U.S. subsidiary, Milla Pharmaceuticals Inc., announced the direct commercialization and launch of Sodium Acetate Injection 2mEq/mL in 20mL, 50mL, and 100mL vials. Milla Pharmaceuticals Inc. announced the direct commercialization and launch of Sodium Acetate Injection 2mEq/mL in 20mL, 50mL, and 100mL vials. Share Sodium Acetate Injection, USP is indicated as a source of sodium for addition to large volume intravenous fluids to prevent or correct hyponatremia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions. 'We continue supplying Sodium Acetate in the U.S. throughout this time of shortage as we have been doing over the last four years, but we are now proudly addressing the shortage directly. Thanks to our own commercial organization, we are now able to provide U.S. patients with the medicines they need most in an even more efficient way. 'This important milestone represents the company's continued investment in and increasing internal dedication to serving the U.S. marketplace, especially for products which have been or continue to be reported in shortage,' commented Erik Lazarich, President of U.S. Operations. Please see link for Full Prescribing Information. About & Milla Pharmaceuticals At our mission is all about Making Affordable Medicines Available To All: we develop value-added generic pharmaceuticals, solve product shortages and fill unmet medical needs so that patients can continue their treatment. At the same time, we are reducing costs to the healthcare system and increasing customer convenience for a more sustainable world. Milla Pharmaceuticals Inc., the U.S. subsidiary of is engaged in the development, licensing, acquisition, and commercialization of generic prescription drugs for the U.S. market, focusing on niche injectable and solution products for hospitals and clinics.
Business Wire
22 minutes ago
- Business Wire
Two-Decade Innovation Journey of MagneRide ® Magneto‑Rheological Dampers
MUNICH--(BUSINESS WIRE)--When BWI Group invented and launched the MagneRide ® magneto‑rheological damper in 2002, the company has propelled MagneRide ® on an extraordinary voyage of technical innovation—an adventure of innovation, challenge and bold breakthroughs. Every generation of MagneRide ® embodies BWI Group's relentless pursuit of sharper vehicle dynamics and superior ride comfort. Constant innovation drives the company to perfect its craft, ensuring that each new iteration delivers a palpably better driving experience. MagneRide ® has elevated vehicle handling and comfort while widening its reach from exotic super‑cars and premium nameplates to a far broader market. First Generation: Started from laboratory magic The story begins in a laboratory brimming with curiosity and ambition. In 2002 the first‑generation MagneRide damper was mass produced for the very first time, endowing the debut application—the Cadillac STS—with unprecedented handling prowess. Second Generation: Reinforced system favoured by super‑cars The second‑generation MagneRide ® damper entered the market in 2006. Upgraded magneto‑rheological fluid and a newly designed piston armed the system for both enhanced comfort and assured control in varied conditions. Europe's top super‑car marques soon extended olive branches, validating MagneRide's unparalleled competitiveness in the high‑performance arena. Third Generation: Leap with speed & passion In 2011, the third‑generation MagneRide ® damper's evolution came with dual‑coil technology pushing response frequency to 1,000 adjustments per second. Meanwhile, dual‑layer sealing made the system more durable, and slashed maintenance costs. Fourth Generation: Benchmark in smart‑drive era Arriving in 2020, the latest generation of MagneRide ® suspension system once again stunned the industry and raised the bar for future mobility. Thanks to a cutting‑edge ECU, wheel‑end accelerometers and an IMU, magneto‑rheological fluid reacts in a lightning‑quick 0.5 millisecond. BWI Group's proprietary algorithmic refinements significantly enhance vehicle stability, ushering in a brand‑new driving paradigm. The latest MagneRide ® suspension system endures more than 300,000 km of gruelling service and operates flawlessly in extremes ranging from −30 °C to 105 °C. It conquers every environment beyond the laboratory, and many flagship models have adopted the system. The fourth generation MagneRide ® suspension system paves the way for boundless possibilities in automotive innovation. From the inaugural invention, through the benchmark‑setting fourth generation, every stride attests to BWI Group's tireless quest for technical excellence and precise understanding of market needs.
Yahoo
43 minutes ago
- Yahoo
Why Regency Centers, Tyson Foods, And Pfizer Are Winners For Passive Income
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors. Regency Centers, Tyson Foods, and Pfizer have rewarded shareholders for years and recently announced dividend increases. These companies currently offer dividend yields of up to 7%. Regency Centers Regency Centers Corp. (NASDAQ:REG) is a real estate investment trust that specializes in owning, operating, and developing shopping centers in suburban areas. Don't Miss: Accredited investors can —with up to 120% bonus shares—before this Uber-style disruption hits the public markets $100k+ in investable assets? – no cost, no obligation. The company has raised its dividends every year for the last 11 years. In its most recent dividend hike announcement on Nov. 7, it increased the quarterly payout by 5.2% to $0.705 per share, equal to an annual figure of $2.82 per share. More recently, in its dividend announcement on May 6, the company maintained the payout at the same level. Currently, the dividend yield on the stock is 4.04%. Regency Centers' annual revenue as of March 31 stood at $1.47 billion. The company on April 29 posted Q1 2025 revenues of $380.91 million and EPS of $1.15, both coming in above the consensus estimates. Check out this article by Benzinga for four analysts' insights on Regency Centers. Trending: This AI-Powered Trading Platform Has 5,000+ Users, 27 Pending Patents, and a $43.97M Valuation — Tyson Foods Tyson Foods Inc. (NYSE:TSN) is a global food company, specializing in chicken, beef, and pork, as well as a variety of prepared foods. Tyson Foods has increased its dividends consecutively for the last 12 years. In its most recent dividend hike announcement on Aug. 8, the board raised the quarterly payout from $0.49 to $0.50 per share, equaling an annual figure of $2 per share. More recently, in its dividend announcement on May 8, the company maintained the payout at the same level. The current dividend yield is 3.74%. Tyson Foods' annual revenue as of March 31 stood at $53.62 billion. In its Q2 2025 earnings report on May 5, the company posted revenues of $13.07 billion, missing the consensus estimate of $13.14 billion, while EPS of $0.92 came in above the consensus of $ Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, and sells biopharmaceutical products in the U.S. and internationally. Pfizer has increased its dividends every year for the last 15 years. In its most recent dividend hike announcement on Dec. 12, it raised the quarterly payout from $0.42 to $0.43 per share, which is equal to an annual figure of $1.72 per share. More recently, in its dividend announcement on June 25, the company maintained the payout at the same level. The dividend yield on the stock currently stands at 7.03%. Pfizer's annual revenue as of March 31 was $62.46 billion. The company on April 29 posted Q1 2025 revenues of $13.71 billion, below the consensus estimate of $13.95 billion, while EPS of $0.92 beat the consensus of $0.67. Regency Centers, Tyson Foods, and Pfizer are good choices for investors seeking reliable passive income. Their dividend yields of up to 7% and long history of consistent hikes make them attractive to income-focused investors. Check out this article by Benzinga for three more stocks offering high dividend yields. Read Next: If there was a new fund backed by Jeff Bezos offering a ? Image: Shutterstock This article Why Regency Centers, Tyson Foods, And Pfizer Are Winners For Passive Income originally appeared on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
